Clinical Trials

Odevixibat is being evaluated in an open-label Phase 3 clinical trial, PEDFIC 2, in patients with PFIC (NCT03659916), as well as a Phase 3 clinical trial, BOLD, in patients with biliary atresia (NCT04336722).

For additional information about the status of our studies or for questions, contact medinfo@albireopharma.com or complete the form below.

(Required)
(Required)
(Required)